These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 17690349)
21. Canadian High Court upholds Glaxo Wellcome AZT patent. AIDS Policy Law; 2002 Dec; 17(22):3. PubMed ID: 12510642 [No Abstract] [Full Text] [Related]
22. EU court gets tough on patent extensions for combo products. Waters H Nat Med; 2012 Jan; 18(1):4. PubMed ID: 22227647 [No Abstract] [Full Text] [Related]
23. Indian biogenerics industry emerges. Jayaraman KS Nat Biotechnol; 2003 Oct; 21(10):1115-6. PubMed ID: 14520378 [No Abstract] [Full Text] [Related]
24. Court dismisses Eli Lilly's case against generic drug makers. Elliott R Can HIV AIDS Policy Law Rev; 2001; 6(1-2):60. PubMed ID: 11837032 [No Abstract] [Full Text] [Related]
25. Impact of India's new patents law 2005: a physician's perspective. Lele RD J Assoc Physicians India; 2005 Aug; 53():671-5. PubMed ID: 16398073 [No Abstract] [Full Text] [Related]
26. Indian pharmaceutical patent prosecution: The changing role of Section 3(d). Sampat BN; Shadlen KC PLoS One; 2018; 13(4):e0194714. PubMed ID: 29608604 [TBL] [Abstract][Full Text] [Related]
27. Indian generic drug production. Benefits of EU-India free trade agreement. Ager B BMJ; 2011 Apr; 342():d2439. PubMed ID: 21502277 [No Abstract] [Full Text] [Related]
28. India's patent ecosystem - encouraging strong patents or discouraging innovation? Harrison C Nat Rev Drug Discov; 2013 Oct; 12(10):732-3. PubMed ID: 24080690 [No Abstract] [Full Text] [Related]
29. International trade and Canadian patent law. Elliott R Can HIV AIDS Policy Law Rev; 2001; 6(1-2):47-53. PubMed ID: 11837027 [No Abstract] [Full Text] [Related]
30. Patent litigation in India continues to throw up new challenges. Reddy Thikkavarapu P Pharm Pat Anal; 2016 Jul; 5(4):211-6. PubMed ID: 27348790 [TBL] [Abstract][Full Text] [Related]
31. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime. Halliburton M Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158 [TBL] [Abstract][Full Text] [Related]
32. Engineered in India--patent law 2.0. Castellani JJ N Engl J Med; 2013 Nov; 369(22):2163. PubMed ID: 24283241 [No Abstract] [Full Text] [Related]
33. A victory for global public health in the Indian Supreme Court. 't Hoen E J Public Health Policy; 2013 Aug; 34(3):370-4. PubMed ID: 23677206 [TBL] [Abstract][Full Text] [Related]
34. A modest but meaningful decision for Indian drug patents. Attaran A Lancet; 2014 Aug; 384(9942):477-9. PubMed ID: 24976117 [No Abstract] [Full Text] [Related]
35. Pharmaceutical patent life-cycle management after KSR v. Teleflex. Furrow ME Food Drug Law J; 2008; 63(1):275-320. PubMed ID: 18561462 [No Abstract] [Full Text] [Related]
36. Physicians and patent law. Attaran A Lancet; 2003 Feb; 361(9357):613-4. PubMed ID: 12598170 [No Abstract] [Full Text] [Related]
38. Will the refusal of patent protection for GlivecĀ® discourage future pharmaceutical innovation in India? Albutt J Pharm Pat Anal; 2013 Jul; 2(4):439-41. PubMed ID: 24237119 [No Abstract] [Full Text] [Related]
39. Federal court raises the bar for overturning patents. Schubert C Nat Med; 2011 Jul; 17(7):758. PubMed ID: 21738135 [No Abstract] [Full Text] [Related]
40. Enforcing pharmaceutical and biotech patent rights in China. Zhang YP; Deng MM Nat Biotechnol; 2008 Nov; 26(11):1235-40. PubMed ID: 18997760 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]